Compare Incyte Corporation (INCY) vs Modine Manufacturing Company (MOD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Modine Manufacturing Company — how do they compare? Incyte Corporation trades at $118.33 (market cap $23.11B), while Modine Manufacturing Company trades at $235.83 (market cap $12.18B). The key difference: Incyte Corporation is the larger of the two by market cap, and Incyte Corporation is trading nearer its 52-week high, Modine Manufacturing Company nearer its low. Which is the better fit depends on your goals.
| INCY | MOD | |
|---|---|---|
Market Cap | $23.11B | $12.18B |
Sector | Health | Technology |
52-Week High | $118.52 | $306.89 |
52-Week Low | $67.38 | $93.71 |
Enterprise Value | $19.13B | $12.54B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
MOD trades at $227.88, down 0.64% today, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $1.71 exceeding expectations. Revenue reached $2.58B in 2025, though net income margin is modest at 3.82%. Recent news includes institutional buying and executive appointments, while technical support sits near $221.
Analyst consensus is bullish with a $328.80 price target, but high P/E of 101.48 suggests premium valuation. Risks include margin pressure from supply chain challenges and competitive threats in data center cooling. The stock offers growth potential if margin expansion continues, but investors face volatility from technical weakness and execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Modine Manufacturing Company
Modine Manufacturing Company is a global leader in thermal management technology and solutions. The company engineers, manufactures, and markets heat transfer products for a wide range of applications across the automotive, commercial, industrial, and HVAC (heating, ventilation, and air conditioning) markets. Modine's products include engine cooling systems, heat exchangers, and ventilation systems, providing critical thermal solutions for vehicles, data centers, and various equipment worldwide.
Read more on MOD →
